Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
101
- +1 vs. Q1 2026
- Total value $33.69M
Superinvestors holding PLX
0
- None of the superinvestors held PLX at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by PLX insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Dec 19, 2025 | Bashan DrorPRESIDENT AND CEO | PPurchaseCommon Stock | +56K | $1.81 | +$101.36K | 188.52K | +42.3% | SEC |
| Nov 19, 2025 | Nov 18, 2025 | Bar-Shalev AmosDirector | SSaleCommon Stock | −168 | $1.87 | −$314.16 | 0 | −100.0% | SEC |
| Aug 12, 2025 | Jun 10, 2025 | Schwartz AharonDirector | PPurchaseCommon Stock | +129K | $1.60 | +$206.4K | 303K | +74.1% | SEC |
| Oct 20, 2023 | Oct 19, 2023 | Bashan DrorPRESIDENT AND CEO | PPurchaseCommon Stock | +64.52K | $1.4025 | +$90.48K | 132.52K | +94.9% | SEC |
| Jan 5, 2023 | Jan 3, 2023 | Schwartz AharonDirector | PPurchaseCommon Stock | +110K | $1.42 | +$156.2K | 174K | +171.9% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in PLX at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,046,650 | $9.43M | 0.00% | +429,688+11.9% | Added |
| RENAISSANCE TECHNOLOGIES LLC | 1,096,000 | $2.55M | 0.00% | −128,800−10.5% | Reduced |
| STATE STREET CORP | 983,582 | $2.29M | 0.00% | +10,767+1.1% | Added |
| GEODE CAPITAL MANAGEMENT, LLC | 979,995 | $2.28M | 0.00% | +114,697+13.3% | Added |
| NORTHERN TRUST CORP | 922,340 | $2.15M | 0.00% | +36,892+4.2% | Added |